FMC stock holds mid-range as latest quarter underpins dialysis outlook
Published on 08/31/2026 at 07:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
FMC stock (ISIN DE0005785802) is trading at EUR 39.920 on Xetra, placing the shares in the middle of their 52-week range as of August 29, 2026.
The latest reported quarter showed revenue of EUR 4.79 billion and operating income of EUR 315 million, giving investors a current view of how FMC's dialysis business supports the share price level.
At EUR 39.920, FMC shares stand EUR 7.940 below the 52-week high of EUR 47.860 and EUR 5.350 above the 52-week low of EUR 34.570, which highlights that the stock is trading closer to the center of its recent band than to either extreme.
Quarterly figures frame valuation
In the most recent quarter, FMC reported revenue of EUR 4.79 billion, a figure that underpins expectations for the scale of the group's global dialysis operations in 2026.
Operating income reached EUR 315 million in the same period, providing a measure of profitability that investors can set against the share price of EUR 39.920 as of August 29, 2026.
Because FMC shares are EUR 7.940 below the 52-week high, the market is valuing the company at a discount to the peak reached earlier in the year while still keeping the stock EUR 5.350 above the 52-week low.
Position in the 52-week band
The current EUR 39.920 price level places FMC stock at a point where the gap to the high of EUR 47.860 is wider than the distance to the low of EUR 34.570, which suggests that the shares have room on both sides of the trading range.
From the start of the year, the shares have moved within this 52-week corridor, and the present positioning gives investors a concrete sense of how far the stock is from both the most optimistic and most cautious market readings embedded in the band.
With the latest quarterly revenue of EUR 4.79 billion and operating income of EUR 315 million available as a reference, the current mid-range price of EUR 39.920 offers a link between operational performance and the 52-week chart picture.
Read more
Investor Relations
Dialysis services as core business
FMC's core business centers on providing dialysis treatments and related services for patients with chronic kidney failure, which makes the company's revenue of EUR 4.79 billion in the latest quarter a direct reflection of demand for these medical services.
The operating income of EUR 315 million in that period indicates how the company's cost structure and pricing combine to generate earnings from its dialysis clinics and products, a key factor for investors assessing the sustainability of current margins.
In many markets, the company operates dialysis centers under long-term reimbursement arrangements with health systems and insurers, so the latest quarterly figures help investors estimate how stable cash flows from these contracts support the share price of EUR 39.920 as of August 29, 2026.
Shares anchored by recent price level
FMC shares closed at EUR 39.920 on August 29, 2026, and this closing price serves as a current anchor point for investors tracking the stock.
Because that closing level is EUR 7.940 below the 52-week high of EUR 47.860, the stock trades at a measurable discount to its most optimistic price over the past year while remaining EUR 5.350 above the 52-week low of EUR 34.570.
This quantified comparison within the 52-week range, combined with the latest quarterly revenue of EUR 4.79 billion and operating income of EUR 315 million, gives investors a numerically grounded picture of how FMC's operational scale supports the present share price.
Fact box
Company: FMC
ISIN: DE0005785802
Ticker: FMC
Exchange: Xetra
Price (as of August 29, 2026): EUR 39.920
Sector / Industry: Health care / dialysis services
Index membership: DAX
